Phesgo
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Phesgo
- Generic name
- PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF
- Manufacturer
- Genentech, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 27dd5e6b-72cd-458d-a015-cf4dab5800da
- SPL ID
- 476f0283-10b7-41f4-ade5-f16f4303e8ac
- Version
- 18
- Effective date
- 2026-09-23
- Source export date
- 2026-11-13
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:31:59
| Harmonized routes |
|---|
| SUBCUTANEOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 761170 | derived:openfda.application_number |
| application number | BLA761170 | openfda.application_number | |
| brand name | Phesgo | openfda.brand_name | |
| generic name | PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF | openfda.generic_name | |
| manufacturer name | Genentech, Inc. | openfda.manufacturer_name | |
| ndc | package | 50242-260-86 | openfda.package_ndc |
| ndc | package | 50242-245-01 | openfda.package_ndc |
| ndc | package | 50242-245-86 | openfda.package_ndc |
| ndc | package | 50242-260-01 | openfda.package_ndc |
| ndc | product | 50242-260 | openfda.product_ndc |
| ndc | product | 50242-245 | openfda.product_ndc |
| ndc11 | package | 50242024501 | derived:openfda.package_ndc |
| ndc11 | package | 50242024586 | derived:openfda.package_ndc |
| ndc11 | package | 50242026086 | derived:openfda.package_ndc |
| ndc11 | package | 50242026001 | derived:openfda.package_ndc |
| rxcui | 2382604 | openfda.rxcui | |
| rxcui | 2383305 | openfda.rxcui | |
| rxcui | 2383307 | openfda.rxcui | |
| rxcui | 2382609 | openfda.rxcui | |
| spl id | 476f0283-10b7-41f4-ade5-f16f4303e8ac | id | |
| spl set id | 27dd5e6b-72cd-458d-a015-cf4dab5800da | set_id | |
| unii | K16AIQ8CTM | openfda.unii | |
| unii | P188ANX8CK | openfda.unii | |
| unii | 743QUY4VD8 | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning. Cardiomyopathy: PHESGO administration can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue PHESGO for cardiomyopathy. ( 2.3 , 5.1 ) Embryo-fetal Toxicity: Exposure to PHESGO can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception. ( 5.2 , 8.1 , 8.3 ) Pulmonary Toxicity: Discontinue PHESGO for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. ( 5.3 ) Cardiomyopathy PHESGO administration can result in subclinical and clinical cardiac failure. The incidence and severity were highest in patients receiving PHESGO with anthracycline-containing chemotherapy regimens. Evaluate cardiac function prior to and during treatment with PHESGO. Discontinue PHESGO treatment in patients receiving adjuvant therapy and withhold PHESGO in patients with metastatic disease for clinically significant decrease in left ventricular function [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ] . Embryo-fetal Toxicity Exposure to PHESGO can result in embryo-fetal death and birth defects, including oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception [see Warnings and Precautions (5.2) and Use in Specific Populations (8.1) , (8.3) ]. Pulmonary Toxicity PHESGO administration can result in serious and fatal pulmonary toxicity. Discontinue PHESGO for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Monitor patients until symptoms completely resolve [see Warnings and Precautions (5.3) ].
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS Exacerbation of Chemotherapy-Induced Neutropenia. ( 5.4 ) Hypersensitivity and Administration-Related Reactions (ARRs): Monitor patients for systemic hypersensitivity reactions. Permanently discontinue PHESGO in patients who experience anaphylaxis or severe hypersensitivity reactions. ( 5.5 ) 5.1 Cardiomyopathy PHESGO can cause hypertension, arrhythmias, left ventricular cardiac dysfunction, disabling cardiac failure, cardiomyopathy, and cardiac death [see Boxed Warning: Cardiomyopathy ]. PHESGO can cause asymptomatic decline in LVEF. An increased incidence of LVEF decline has been observed in patients treated with intravenous pertuzumab, intravenous trastuzumab, and docetaxel. A 4-6 fold increase in the incidence of symptomatic myocardial dysfunction has been reported among patients receiving trastuzumab, with the highest absolute incidence occurring when trastuzumab was administered with an anthracycline. Patients who receive anthracycline after stopping PHESGO may also be at increased risk of cardiac dysfunction [see Drug Interactions (7) and Clinical Pharmacology (12.2) ]. Cardiac Monitoring Prior to initiation of PHESGO, conduct a thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan. During treatment with PHESGO, assess LVEF at regular intervals [see Dosage and Administration (2.4) ]. If after a repeat assessment within approximately 3 weeks, the LVEF has not improved, has declined further, and/or the patient is symptomatic, permanently discontinue PHESGO. Following completion of PHESGO, continue to monitor for cardiomyopathy and assess LVEF measurements every 6 months for at least 2 years as a component of adjuvant therapy. PHESGO In the FeDeriCa trial, the percentage of patients with at least one cardiac disorder was 22% in the PHESGO arm. The most frequent cardiac adverse reaction in the PHESGO arm was ejection fraction decreased. The incidence of cardiac failure (NYHA Class III/IV) with a LVEF decline ≥ 10% and a drop to less than 50% was 0.8% in the PHESGO arm. Confirmed asymptomatic or mildly symptomatic (NYHA Class II) declines in LVEF ≥ 10% and a drop to less than 50% was 1.2% in the PHESGO arm [see Adverse Reactions (6.1) ] . PHESGO and/or intravenous pertuzumab and trastuzumab have not been studied in patients with a pretreatment LVEF value of < 55% (EBC) or <50% (MBC); a prior history of CHF, conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment or a cumulative prior anthracycline exposure to > 360 mg/m 2 of doxorubicin or its equivalent. 5.2 Embryo-Fetal Toxicity PHESGO can cause fetal harm when administered to a pregnant woman. In post-marketing reports, use of intravenous trastuzumab during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. In an animal reproduction study, administration of intravenous pertuzumab to pregnant cynomolgus monkeys during the period of organogenesis resulted in oligohydramnios, delayed fetal kidney development, and embryo-fetal death at exposures 2.5 to 20 times the exposure in humans at the recommended dose, based on C max . Verify the pregnancy status of females of reproductive potential prior to the initiation of PHESGO. Advise pregnant women and females of reproductive potential that exposure to PHESGO during pregnancy or within 7 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of PHESGO [see Use in Specific Populations (8.1 , 8.3) and Clinical Pharmacology (12.3) ]. 5.3 Pulmonary Toxicity PHESGO can cause serious and fatal pulmonary toxicity. These adverse reactions have been reported with intravenous trastuzumab. Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis. Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest, appear to have more severe toxicity. 5.4 Exacerbation of Chemotherapy-Induced Neutropenia PHESGO may exacerbate chemotherapy-induced neutropenia. In randomized controlled clinical trials with intravenous trastuzumab, Grade 3-4 neutropenia and febrile neutropenia were higher in patients receiving trastuzumab in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone. The incidence of septic death was similar among patients who received trastuzumab and those who did not. 5.5 Hypersensitivity and Administration-Related Reactions Severe administration-related reactions (ARRs), including hypersensitivity, anaphylaxis, and events with fatal outcomes, have been associated with intravenous pertuzumab and trastuzumab. Patients experiencing dyspnea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of a severe or of a fatal ARR. In the FeDeriCa trial, the incidence of hypersensitivity was 1.2% in the PHESGO arm. Administration-related reactions occurred in 21% of patients who received PHESGO. In the PHESGO arm, the most common administration-related reactions were injection site reaction (15%) and injection site pain (2%). Closely monitor patients during and for 30 minutes after the injection of initial dose and during and for 15 minutes following subsequent injections of maintenance dose of PHESGO. If a significant injection-related reaction occurs, slow down or pause the injection and administer appropriate medical therapies. Evaluate and carefully monitor patients until complete resolution of signs and symptoms. Permanently discontinue with PHESGO in patients who experience anaphylaxis or severe injection-related reactions. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use. For patients experiencing reversible Grade 1 or 2 hypersensitivity reactions, consider pre-medication with an analgesic, antipyretic, or an antihistamine prior to readministration of PHESGO [see Adverse Reactions (6.1) ] . PHESGO is contraindicated in patients with known hypersensitivity to pertuzumab, trastuzumab, hyaluronidase or to any of its excipients [see Contraindications (4) ] .
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the label: Cardiomyopathy [see Warnings and Precautions (5.1) ] Embryo-Fetal Toxicity [see Warnings and Precautions (5.2) ] Pulmonary Toxicity [see Warnings and Precautions (5.3) ] Exacerbation of Chemotherapy-Induced Neutropenia [see Warnings and Precautions (5.4) ] Hypersensitivity and Administration-Related Reactions [see Warnings and Precautions (5.5) ] Neoadjuvant and Adjuvant Treatment of Breast Cancer The most common adverse reactions (>30%) with PHESGO were alopecia, nausea, diarrhea, anemia, and asthenia. ( 6.1 ) Metastatic Breast Cancer (based on intravenous pertuzumab ) The most common adverse reactions (> 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Neoadjuvant and Adjuvant Treatment of Breast Cancer The safety of PHESGO was evaluated in an open-label, multicenter, randomized trial (FeDeriCa) conducted in 500 patients with HER2 overexpressing early breast cancer [see Clinical Studies (14.2) ] . Patients were randomized to receive either PHESGO (1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase/15 mL) followed every 3 weeks by a maintenance dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase/10 mL or the recommended dosages for intravenous pertuzumab and intravenous trastuzumab. Patients were randomized to receive 8 cycles of neoadjuvant chemotherapy with concurrent administration of 4 cycles of either PHESGO or intravenous pertuzumab and trastuzumab during cycles 5-8, followed by surgery. Following surgery, patients continued therapy with PHESGO alone or intravenous pertuzumab and trastuzumab (intravenous or subcutaneously administered) as treated prior to surgery, for an additional 14 cycles, to complete 18 cycles. The median duration of treatment for PHESGO was 24 weeks (range: 0-42 weeks). Serious adverse reactions occurred in 16% of patients who received PHESGO. Serious adverse reactions in > 1% of patients included febrile neutropenia (4%), neutropenic sepsis (1%), and neutrophil count decreased (1%). One fatal adverse reaction occurred in 1/248 (0.4%) of patients, which was due to acute myocardial infarction, and occurred prior to the start of HER2 targeted treatment with PHESGO. Adverse reactions resulting in permanent discontinuation of any study drug occurred in 8% of patients on the PHESGO arm. Adverse reactions which resulted in permanent discontinuation of PHESGO were ejection fraction decreased (1.2%), cardiac failure (0.8%), and pneumonitis/pulmonary fibrosis (0.8%). Dosage interruptions due to an adverse reaction occurred in 40% of patients who received PHESGO. Adverse reactions which required dosage interruption in > 1% of patients who received PHESGO included neutropenia (8%), neutrophil count decreased (4%), and diarrhea (7%). Table 3 summarizes the adverse reactions in FeDeriCa. Table 3: Adverse Reactions (≥5%) in Patients Who Received PHESGO in FeDeriCa Adverse Reactions PHESGO (n=248) Intravenous pertuzumab plus intravenous or subcutaneous trastuzumab (n=252) All Grades % Grades 3 – 4 % All Grades % Grades 3 – 4 % Skin and subcutaneous tissue disorders Alopecia 77 0 71 0.4 Dry skin 15 0.4 13 0 Rash 16 0.4 21 0 Nail discoloration 9 0 6 0 Erythema 9 0 5 0 Dermatitis 7 0 6 0 Nail disorder 7 0 7 0.4 Palmar-plantar erythrodysaesthesia syndrome 6 0.8 5 0.4 Gastrointestinal disorders Nausea 60 2 61 1.6 Diarrhea 60 7 57 4.8 Stomatitis 25 0.8 24 0.8 Constipation 22 0 21 0 Vomiting 20 0.8 19 1.2 Dyspepsia 14 0 12 0 Hemorrhoids 9 0 4.0 0 Abdominal pain upper 8 0 6 0 Abdominal pain 9 0.4 6 0 Blood and lymphatic system disorders Anemia 36 1.6 43 4.4 Neutropenia 22 14 27 14 Leukopenia 9 2.4 14 2 Febrile neutropenia 7 7 6 6 General disorders and administration site conditions Asthenia 31 0.4 32 2.4 Fatigue 29 2 24 2 Mucosal inflammation 15 0.8 20 1.2 Injection site reaction 15 0 0.8 0 Pyrexia 13 0 16 0.4 Edema peripheral 8 0 10 0 Malaise 7 0 6 0.4 Influenza-like illness 5 0 3.6 0 Nervous system disorders Dysgeusia 17 0 14 0 Peripheral sensory neuropathy 16 0.8 14 0.4 Headache 17 0 25 0.8 Neuropathy peripheral 12 0.4 15 2 Paresthesia 10 0.8 8 0 Dizziness 13 0 11 0 Investigations Weight decreased 11 0.8 6 0.8 Musculoskeletal and connective tissue disorders Myalgia 25 0.4 19 0.4 Arthralgia 24 0 28 0.4 Back pain 10 0 4.8 0 Bone pain 7 0 5 0 Pain in extremity 6 0 8 0 Muscle spasms 6 0 7 0 Musculoskeletal pain 6 0.4 8 0 Respiratory, thoracic and mediastinal disorder Cough 15 0.4 13 0 Epistaxis 12 0 14 0.4 Dyspnea 10 1.2 5 0 Rhinorrhea 7 0 4.4 0 Infections and infestations Upper respiratory tract infection 11 0 8 0.8 Nasopharyngitis 9 0 10 0 Paronychia 7 0.4 3.6 0 Urinary tract infection 7 0.4 5 0 Injury, poisoning and procedural complications Procedural pain 13 0 10 0 Radiation skin injury 19 0.4 19 0.4 Infusion related reaction 3.6 0 15 0.8 Metabolism and nutrition disorders Decreased appetite 17 0.8 19 0.4 Hypokalemia 7 1.6 8 0 Psychiatric disorders Insomnia 17 0 13 0.4 Eye disorders Lacrimation increased 5 0.4 6 0 Dry eye 5 0.4 3.2 0 Vascular disorders Hot flush 12 0 13 0 Clinically relevant adverse reactions in <5% of patients who received PHESGO include ejection fraction decreased (3.6%) and pruritus (3.2%). In the FeDeriCa trial, when PHESGO was administered alone, adverse reactions occurred in <10% of patients with the exception of radiation skin injury (20%), arthralgia (19%), diarrhea (17%), injection site reaction (13%), dyspepsia (12%), asthenia (11%), hot flush (11%), and pruritus (10%). Table 4 summarizes the laboratory abnormalities in FeDeriCa. Table 4: Select Laboratory Abnormalities (≥5%) that Worsened from Baseline in Patients Who Received PHESGO in FeDeriCa The denominator used to calculate the rate varied from 163 to 252 based on the number of patients with a baseline value and at least one post-treatment value. Laboratory Abnormality PHESGO (n=248) Intravenous pertuzumab plus intravenous or subcutaneous trastuzumab (n=252) All Grades % Grades 3 – 4 % All Grades % Grades 3 – 4 % Hematology Hemoglobin (low) 90 2.8 92 4.4 Lymphocytes, Absolute (low) 89 37 88 36 Total Leukocyte Count (low) 82 25 78 25 Neutrophils, Total Absolute (low) 68 30 67 33 Platelet (low) 27 0 28 0.4 Chemistry Creatinine (high) 84 0 87 0.4 Alanine aminotransferase (high) 58 1.6 68 2.4 Aspartate aminotransferase (high) 50 0.8 58 0.8 Potassium (low) 17 5.2 17 2.8 Albumin (low) 16 0 20 0.4 Potassium (high) 13 1.2 9 0 Sodium (low) 13 0.4 10 1.6 Bilirubin (high) 9 0 9 0.4 Glucose (low) 9 0 9 0.4 Sodium (high) 7 0.8 10 0.8 Other Clinical Trials Experience The safety of the addition of intravenous pertuzumab to trastuzumab in combination with chemotherapy has been established in studies conducted in patients with HER2 overexpressing early breast cancer. The following adverse reactions have been reported following administration of intravenous pertuzumab and trastuzumab: diarrhea, alopecia, nausea, fatigue, neutropenia, vomiting, peripheral neuropathy, constipation, anemia, asthenia, mucosal inflammation, myalgia, and thrombocytopenia. Refer to the Prescribing Information for pertuzumab for more information. The safety of intravenous pertuzumab, trastuzumab and docetaxel has been established in patients with HER2 overexpressing metastatic breast cancer. The following adverse reactions have been reported following administration of intravenous pertuzumab and trastuzumab: diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy. Refer to the Prescribing Information for pertuzumab for more information. 6.2 Postmarketing Experience The following adverse reactions have been identified with the use of intravenous trastuzumab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Glomerulopathy Immune thrombocytopenia Tumor lysis syndrome (TLS): Patients with significant tumor burden (e.g. bulky metastases) may be at a higher risk. Patients could present with hyperuricemia, hyperphosphatemia, and acute renal failure which may represent possible TLS. Providers should consider additional monitoring and/or treatment as clinically indicated.
adverse reactions table
<table width="100%" ID="t3"> <caption>Table 3: Adverse Reactions (≥5%) in Patients Who Received PHESGO in FeDeriCa</caption> <col width="40%" align="left" valign="middle"/> <col width="15%" align="center" valign="middle"/> <col width="15%" align="center" valign="middle"/> <col width="15%" align="center" valign="middle"/> <col width="15%" align="center" valign="middle"/> <thead> <tr styleCode="Botrule"> <th styleCode="Lrule Rrule" valign="bottom">Adverse Reactions</th> <th styleCode="Rrule" colspan="2" valign="middle">PHESGO (n=248)</th> <th styleCode="Rrule" colspan="2" valign="top">Intravenous pertuzumab plus intravenous or subcutaneous trastuzumab (n=252)</th> </tr> <tr> <th styleCode="Lrule Rrule"/> <th styleCode="Rrule">All Grades %</th> <th styleCode="Rrule">Grades 3 – 4 %</th> <th styleCode="Rrule">All Grades %</th> <th styleCode="Rrule">Grades 3 – 4 %</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Skin and subcutaneous tissue disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Alopecia</td> <td styleCode="Rrule">77</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">71</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Dry skin</td> <td styleCode="Rrule">15</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Rash</td> <td styleCode="Rrule">16</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">21</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Nail discoloration</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Erythema</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Dermatitis</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Nail disorder</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Palmar-plantar erythrodysaesthesia syndrome</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0.8</td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Gastrointestinal disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Nausea</td> <td styleCode="Rrule">60</td> <td styleCode="Rrule">2</td> <td styleCode="Rrule">61</td> <td styleCode="Rrule">1.6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Diarrhea</td> <td styleCode="Rrule">60</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">57</td> <td styleCode="Rrule">4.8</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Stomatitis</td> <td styleCode="Rrule">25</td> <td styleCode="Rrule">0.8</td> <td styleCode="Rrule">24</td> <td styleCode="Rrule">0.8</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Constipation</td> <td styleCode="Rrule">22</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">21</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Vomiting</td> <td styleCode="Rrule">20</td> <td styleCode="Rrule">0.8</td> <td styleCode="Rrule">19</td> <td styleCode="Rrule">1.2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Dyspepsia</td> <td styleCode="Rrule">14</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">12</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Hemorrhoids</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">4.0</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Abdominal pain upper</td> <td styleCode="Rrule">8</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Abdominal pain</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Blood and lymphatic system disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Anemia</td> <td styleCode="Rrule">36</td> <td styleCode="Rrule">1.6</td> <td styleCode="Rrule">43</td> <td styleCode="Rrule">4.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Neutropenia</td> <td styleCode="Rrule">22</td> <td styleCode="Rrule">14</td> <td styleCode="Rrule">27</td> <td styleCode="Rrule">14</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Leukopenia</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">2.4</td> <td styleCode="Rrule">14</td> <td styleCode="Rrule">2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Febrile neutropenia</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">General disorders and administration site conditions</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Asthenia</td> <td styleCode="Rrule">31</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">32</td> <td styleCode="Rrule">2.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Fatigue</td> <td styleCode="Rrule">29</td> <td styleCode="Rrule">2</td> <td styleCode="Rrule">24</td> <td styleCode="Rrule">2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Mucosal inflammation</td> <td styleCode="Rrule">15</td> <td styleCode="Rrule">0.8</td> <td styleCode="Rrule">20</td> <td styleCode="Rrule">1.2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Injection site reaction</td> <td styleCode="Rrule">15</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">0.8</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Pyrexia</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">16</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Edema peripheral</td> <td styleCode="Rrule">8</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">10</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Malaise</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Influenza-like illness</td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">3.6</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Nervous system disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Dysgeusia</td> <td styleCode="Rrule">17</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">14</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Peripheral sensory neuropathy</td> <td styleCode="Rrule">16</td> <td styleCode="Rrule">0.8</td> <td styleCode="Rrule">14</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Headache</td> <td styleCode="Rrule">17</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">25</td> <td styleCode="Rrule">0.8</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Neuropathy peripheral</td> <td styleCode="Rrule">12</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">15</td> <td styleCode="Rrule">2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Paresthesia</td> <td styleCode="Rrule">10</td> <td styleCode="Rrule">0.8</td> <td styleCode="Rrule">8</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Dizziness</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">11</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Investigations</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Weight decreased</td> <td styleCode="Rrule">11</td> <td styleCode="Rrule">0.8</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0.8</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Musculoskeletal and connective tissue disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Myalgia</td> <td styleCode="Rrule">25</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">19</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Arthralgia</td> <td styleCode="Rrule">24</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">28</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Back pain</td> <td styleCode="Rrule">10</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">4.8</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Bone pain</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Pain in extremity</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">8</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Muscle spasms</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Musculoskeletal pain</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">8</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Respiratory, thoracic and mediastinal disorder</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Cough</td> <td styleCode="Rrule">15</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Epistaxis</td> <td styleCode="Rrule">12</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">14</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Dyspnea</td> <td styleCode="Rrule">10</td> <td styleCode="Rrule">1.2</td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Rhinorrhea</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">4.4</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Infections and infestations</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Upper respiratory tract infection</td> <td styleCode="Rrule">11</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">8</td> <td styleCode="Rrule">0.8</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Nasopharyngitis</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">10</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Paronychia</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">3.6</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Urinary tract infection</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Injury, poisoning and procedural complications</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Procedural pain</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">10</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Radiation skin injury</td> <td styleCode="Rrule">19</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">19</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Infusion related reaction</td> <td styleCode="Rrule">3.6</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">15</td> <td styleCode="Rrule">0.8</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Metabolism and nutrition disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased appetite</td> <td styleCode="Rrule">17</td> <td styleCode="Rrule">0.8</td> <td styleCode="Rrule">19</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Hypokalemia</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">1.6</td> <td styleCode="Rrule">8</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Psychiatric disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Insomnia</td> <td styleCode="Rrule">17</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Eye disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Lacrimation increased</td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Dry eye</td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">3.2</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Vascular disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule">Hot flush</td> <td styleCode="Rrule">12</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">0</td> </tr> </tbody> </table>
adverse reactions table
<table width="100%" ID="t4"> <caption>Table 4: Select Laboratory Abnormalities (≥5%) that Worsened from Baseline in Patients Who Received PHESGO in FeDeriCa <footnote>The denominator used to calculate the rate varied from 163 to 252 based on the number of patients with a baseline value and at least one post-treatment value.</footnote> </caption> <col width="40%" align="left" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> <thead> <tr styleCode="Botrule"> <th styleCode="Lrule Rrule" rowspan="2">Laboratory Abnormality</th> <th styleCode="Rrule" colspan="2" valign="middle">PHESGO (n=248)</th> <th styleCode="Rrule" colspan="2" valign="top">Intravenous pertuzumab plus intravenous or subcutaneous trastuzumab (n=252)</th> </tr> <tr> <th styleCode="Rrule" align="center">All Grades %</th> <th styleCode="Rrule">Grades 3 – 4 %</th> <th styleCode="Rrule">All Grades %</th> <th styleCode="Rrule">Grades 3 – 4 %</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Hematology</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Hemoglobin (low)</td> <td styleCode="Rrule">90</td> <td styleCode="Rrule">2.8</td> <td styleCode="Rrule">92</td> <td styleCode="Rrule">4.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Lymphocytes, Absolute (low)</td> <td styleCode="Rrule">89</td> <td styleCode="Rrule">37</td> <td styleCode="Rrule">88</td> <td styleCode="Rrule">36</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Total Leukocyte Count (low)</td> <td styleCode="Rrule">82</td> <td styleCode="Rrule">25</td> <td styleCode="Rrule">78</td> <td styleCode="Rrule">25</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Neutrophils, Total Absolute (low)</td> <td styleCode="Rrule">68</td> <td styleCode="Rrule">30</td> <td styleCode="Rrule">67</td> <td styleCode="Rrule">33</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Platelet (low)</td> <td styleCode="Rrule">27</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">28</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5"> <content styleCode="bold">Chemistry</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Creatinine (high)</td> <td styleCode="Rrule">84</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">87</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Alanine aminotransferase (high)</td> <td styleCode="Rrule">58</td> <td styleCode="Rrule">1.6</td> <td styleCode="Rrule">68</td> <td styleCode="Rrule">2.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Aspartate aminotransferase (high)</td> <td styleCode="Rrule">50</td> <td styleCode="Rrule">0.8</td> <td styleCode="Rrule">58</td> <td styleCode="Rrule">0.8</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Potassium (low)</td> <td styleCode="Rrule">17</td> <td styleCode="Rrule">5.2</td> <td styleCode="Rrule">17</td> <td styleCode="Rrule">2.8</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Albumin (low)</td> <td styleCode="Rrule">16</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">20</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Potassium (high)</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">1.2</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Sodium (low)</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">0.4</td> <td styleCode="Rrule">10</td> <td styleCode="Rrule">1.6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Bilirubin (high)</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">0.4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Glucose (low)</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">0.4</td> </tr> <tr> <td styleCode="Lrule Rrule">Sodium (high)</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">0.8</td> <td styleCode="Rrule">10</td> <td styleCode="Rrule">0.8</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.